Alexandra James

Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists

Brian G. Feagan, David T. Rubin, Silvio Danese et al. · Clinical Gastroenterology and Hepatology · 2016 · 221 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Vedolizumab as Induction and Maintenance Therapy for Crohnʼs Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy

Bruce E. Sands, William J. Sandborn, Gert Van Assche et al. · Inflammatory Bowel Diseases · 2016 · 184 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the <scp>INBUILD</scp> Trial

Eric L. Matteson, Clive Kelly, Jörg H. W. Distler et al. · Arthritis & Rheumatology · 2022 · 114 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +16

Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age

Vijay Yajnik, Nabeel Khan, Marla C. Dubinsky et al. · Advances in Therapy · 2017 · 94 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +16

The Cost of Transplant Immunosuppressant Therapy: Is This Sustainable?

Alexandra James, Roslyn B. Mannon · Current Transplantation Reports · 2015 · 91 citations · Full text

Pharmacy, Immunology, Pharmacoeconomics +11